Sign In
Buy KCPC
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Key Capital Offers to Help India COVID Crisis with Major Aid Potential via its 24/7 Immune Supplement
10:15am, Thursday, 29'th Apr 2021
MaxCellLife 24/7 Immune Supplement has been Reported Effective for COVID-19, Colds and Flu, with 90% Reduction in COVID-19 Virus Infectivity Additionally Reported Through Independent University Resear
Key Capital HAP-V+ Immune Supplement Reported Effective Against COVID-19, and Colds and Flu
09:30am, Monday, 26'th Apr 2021
90% Reduction in COVID-19 Virus Infectivity Reported Through Independent University Research Study NEW YORK, NY / ACCESSWIRE / April 26, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that Imm
Key Capital Launches Unique Natural Mental Health Supplement - MaxCellLife MIND
09:45am, Thursday, 08'th Apr 2021
MaxCellLife MIND, a Proprietary M.Vaccae and Magnesium Compound, targets the Multi-Billion Anxiety, Stress and Depression Market NEW YORK, NY / ACCESSWIRE / April 8, 2021 / KEY CAPITAL CORPORATION (OT
Key Capital Launches MaxCellLife.com to Market Unique Supplement and Skincare Products
09:30am, Wednesday, 07'th Apr 2021
Jennifer Reilly appointed Marketing Director to Lead MaxCellLife.com Launch NEW YORK, NY / ACCESSWIRE / April 7, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the Company is launching https:/
Key Capital to Focus on Oral Pill Cancer Treatment Success
12:00pm, Thursday, 18'th Mar 2021
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarif
Key Capital Leads Oral Pill Vaccines Race with Immunitor Partnering and Strong Patenting
08:45am, Wednesday, 03'rd Mar 2021
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and Other Diseases, and Viruses NEW YORK, NY / ACCESSWIRE / March 3, 2021 / KEY
Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study
09:15am, Monday, 18'th Jan 2021
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY CAPITAL CORPORATION (
Key Capital Advises Urgent Global Need For COVID-19 Oral Pill Therapeutic Vaccine
09:45am, Wednesday, 06'th Jan 2021
NEW YORK, NY / ACCESSWIRE / January 6, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis. While WHO ad
